Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.63 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22914768 | 0.90 | EGLN2 (0.54) | EGLN2GPR119ARALDH1A1LMNA | |
| SCHEMBL18357677 | 0.90 | EGLN2 (0.54) | EGLN2GPR119ARALDH1A1LMNA | |
| SCHEMBL22914827 | 0.89 | EGLN2 (0.52) | EGLN2GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL484627 | 0.85 | CYP11B2 (0.53) | EGLN2GPR119ARALDH1A1LMNA | |
| SCHEMBL27031070 | 0.84 | GPR119 (0.60) | EGLN2GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL21521618 | 0.83 | EGLN2 (0.59) | EGLN2GPR119RET | |
| SCHEMBL29461467 | 0.83 | EGLN2 (0.59) | EGLN2GPR119RET | |
| SCHEMBL12006149 | 0.83 | GPR119 (0.46) | EGLN2GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL21877081 | 0.83 | RORC (0.47) | EGLN2GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL15400567 | 0.83 | GPR119 (0.46) | EGLN2GPR119ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001863-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2026-01-01 | — | — | US | disclosed |
| CN-118666853-A | N-methyl N- (6- (methoxy) pyridazin-3-yl) amine derivatives for the treatment of inflammatory airway diseases or fibrotic diseases | 勃林格殷格翰国际有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-114206876-B | N-methyl, N- (6- (methoxy) pyridazin-3-yl) amine derivatives as modulators of Autotaxin (ATX) for the treatment of inflammatory airway diseases or fibrotic diseases | 勃林格殷格翰国际有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4364805-A2 | NOVEL PYRIDAZINES | Boehringer Ingelheim International GmbH (DE) | 2024-05-08 | — | — | EP | disclosed |
| EP-4003999-B1 | 1-(6-(METHOXY)PYRIDAZIN-3-YL)CYCLOPROPANE-1-CARBOXAMIDE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2024-05-01 | — | — | EP | disclosed |
| EP-4003998-B1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2024-03-27 | — | — | EP | disclosed |
| US-20230100516-A1 | PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-03-30 | — | — | US | disclosed |
| US-20230022770-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230022770-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-11485727-B2 | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
| US-11465982-B2 | Pyridazines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-10-11 | — | — | US | disclosed |
| EP-4003999-A1 | 1-(6-(METHOXY)PYRIDAZIN-3-YL)CYCLOPROPANE-1-CARBOXAMIDE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2022-06-01 | — | — | EP | disclosed |
| US-20210024492-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| US-20210024492-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| US-20210024495-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| US-20210024495-A1 | NOVEL PYRIDAZINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | US | disclosed |
| WO-2021013832-A1 | 1-(6-(METHOXY)PYRIDAZIN-3-YL)CYCLOPROPANE-1-CARBOXAMIDE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021013830-A1 | N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465982-B2 | Pyridazines | ENPP2, PLPBP, PRDX5 | EGLN2 3340/4885GPR119 1122/4885AR 4523/4885 |
| US-20210024492-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | EGLN2 4307/4885GPR119 1166/4885AR 4589/4885 |
| US-20230100516-A1 | PYRIDAZINES | ENPP2, PLPBP, PRDX5 | EGLN2 4277/4885GPR119 1741/4885AR 4593/4885 |
| US-20260001863-A1 | NOVEL PYRIDAZINES | ENPP2, LPAR5, LPAR1 | EGLN2 2450/4885GPR119 561/4885AR 2749/4885 |
| US-20210024495-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | EGLN2 4307/4885GPR119 1166/4885AR 4589/4885 |
| US-20230022770-A1 | NOVEL PYRIDAZINES | ENPP2, PLPBP, PRDX6 | EGLN2 4307/4885GPR119 1166/4885AR 4589/4885 |
| US-11485727-B2 | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators | ENPP2, ATXN10, ATXN2L | EGLN2 4003/4885GPR119 1174/4885AR 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.